Eli Lilly & Co. experimental antibody therapy won’t resume

User avatar
AHE
Site Admin
Posts: 3793
Joined: 2020, Sep 14, Mon, 9:56 am

Eli Lilly & Co. experimental antibody therapy won’t resume

Unread post by AHE »

researchers concluded the drug likely wouldn’t help hospitalized Covid-19 patients with advanced cases.

other trials are ongoing to determine whether it helps patients earlier in the disease’s course.

ACTIV-3 was testing a high-dose version of the antibody treatment Lilly is developing with Canadian biotech AbCellera Biologics Inc. in combination with the antiviral drug remdesivir, yet there was no indication it was effective, leading an independent panel to recommend stopping enrollment.

monoclonal antibodies may only work if given early in the course of a coronavirus infection, before the virus has had a chance to penetrate deep into the lungs and cause serious damage.
https://www.msn.com/en-us/health/medica ... r-BB1apZAh
AHE network of sites

Blog: https://www.arkdvd.com/wp
Post Reply